Sonoma Pharmaceuticals, Inc. (SNOA) Key Metrics
SNOA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $5.4M
- Enterprise value
- $1.4M
- P/E (TTM)
- —
- Forward P/E
- 46.1
- PEG ratio
- 1.08
- Price / sales
- 0.2
- Price / book
- 0.9
- EV / EBITDA
- 11.5
- Dividend yield
- —
- Beta
- 1.30
SNOA key metrics, FY2017–FY2026
Fiscal year ended March 31, 2026 · U.S. dollarsSNOA valuation Price multiples at each fiscal year-end price.
Price / sales−3.4%
0.2
FY2026 · hover or tap a bar for each year
FY2017FY2026
Price / book+88.1%
1.2
FY2026 · hover or tap a bar for each year
FY2017FY2026
Free cash flow yield−108.8 pts
−115.0%
FY2026 · hover or tap a bar for each year
FY2017FY2026
SNOA returns How much profit the business earns on the capital it uses.
Return on equity−19.1 pts
−84.6%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Return on invested capital
−441.9%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Return on assets+1.4 pts
−23.0%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Free cash flow margin−19.9 pts
−21.1%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Asset turnover+40.5%
1.41
FY2026 · hover or tap a bar for each year
FY2017FY2026
SNOA per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+0.7%
$11.60
FY2026 · hover or tap a bar for each year
FY2017FY2026
Earnings per share
−$1.89
FY2026 · hover or tap a bar for each year
FY2017FY2026
Free cash flow per share
−$2.45
FY2026 · hover or tap a bar for each year
FY2017FY2026
Book value per share−48.3%
$1.84
FY2026 · hover or tap a bar for each year
FY2017FY2026
Shares outstanding+35.7%
1.7M
FY2026 · hover or tap a bar for each year
FY2017FY2026
SNOA financial health Debt, liquidity and how easily interest is covered.
Debt / equity+293.4%
0.27
FY2026 · hover or tap a bar for each year
FY2017FY2026
Net debt+$3.5M
−$1.6M
FY2026 · hover or tap a bar for each year
FY2017FY2026
Current ratio−18.9%
2.50
FY2026 · hover or tap a bar for each year
FY2017FY2026
Debt / assets+170.8%
0.06
FY2026 · hover or tap a bar for each year
FY2017FY2026
SNOA efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−39 days
86 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Days of inventory−18 days
99 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Days payables outstanding+11 days
43 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Cash conversion cycle−67 days
142 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Capex / revenue+0.4 pts
1.0%
FY2026 · hover or tap a bar for each year
FY2017FY2026
SNOA valuation history
Fiscal year-endToday10-year median
SNOA returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SNOA debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SNOA cash returned to shareholders
DividendsBuybacksFree cash flow
SNOA price vs earnings per share
Share price at year-endEPS (right axis)
SNOA key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $3.6M | $2.7M | — | — | — | — | — | — | — | — |
| Enterprise value | $2.0M | −$2.4M | — | — | — | — | — | — | — | — |
| Price / sales | 0.2 | 0.2 | — | — | — | — | — | — | — | — |
| Price / book | 1.2 | 0.6 | — | — | — | — | — | — | — | — |
| EV / sales | 0.1 | -0.2 | — | — | — | — | — | — | — | — |
| Earnings yield | −88.5% | −127.2% | — | — | — | — | — | — | — | — |
| Free cash flow yield | −115.0% | −6.2% | — | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $2.13 | $2.19 | $3.40 | $19.60 | $80.20 | $148.60 | $98.00 | $169.20 | $662.40 | $1,290.60 |
| Per share | ||||||||||
| Revenue per share | $11.60 | $11.51 | — | — | — | — | — | — | — | — |
| Earnings per share | −$1.89 | −$2.79 | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$2.34 | −$0.07 | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$2.45 | −$0.14 | — | — | — | — | — | — | — | — |
| Cash per share | $1.42 | $4.33 | — | — | — | — | — | — | — | — |
| Book value per share | $1.84 | $3.55 | — | — | — | — | — | — | — | — |
| Tangible book value per share | $1.84 | $3.55 | — | — | — | — | — | — | — | — |
| Capex per share | $0.11 | $0.06 | — | — | — | — | — | — | — | — |
| Debt per share | $0.50 | $0.25 | — | — | — | — | — | — | — | — |
| Shares outstanding | 1.7M | 1.2M | — | — | — | — | — | — | — | — |
| Change in shares outstanding | +35.7% | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −84.6% | −65.5% | −68.5% | −61.8% | −72.3% | −71.9% | −41.1% | −91.4% | −78.0% | 58.8% |
| Return on invested capital (ROIC) | −441.9% | — | −86.1% | −94.1% | −143.4% | −82.6% | −116.1% | −135.9% | −219.9% | −286.1% |
| Return on assets (ROA) | −23.0% | −24.3% | −31.2% | −29.4% | −30.1% | −26.7% | −22.8% | −70.1% | −64.2% | 47.2% |
| Return on tangible assets | −22.7% | −25.2% | −32.8% | −31.7% | −27.0% | −26.4% | −22.7% | −81.7% | −74.6% | 36.4% |
| Free cash flow margin | −21.1% | −1.2% | −19.0% | −48.4% | −34.7% | −19.1% | −26.8% | −62.3% | −75.8% | −66.8% |
| Income quality (OCF / net income) | — | — | — | — | — | — | — | — | — | −0.88 |
| Financial health | ||||||||||
| Total debt | $842,000 | $305,000 | $608,000 | $849,000 | $1.4M | $2.7M | $850,000 | $475,000 | $553,000 | $410,000 |
| Cash & short-term investments | $2.4M | $5.4M | $3.1M | $3.8M | $7.4M | $4.2M | $3.7M | $3.7M | $10.1M | $17.5M |
| Net debt | −$1.6M | −$5.1M | −$2.5M | −$3.0M | −$6.0M | −$1.5M | −$2.8M | −$3.2M | −$9.5M | −$17.1M |
| Debt / equity | 0.27 | 0.07 | 0.10 | 0.11 | 0.16 | 0.50 | 0.15 | 0.05 | 0.04 | 0.02 |
| Debt / assets | 0.06 | 0.02 | 0.04 | 0.05 | 0.07 | 0.18 | 0.06 | 0.03 | 0.03 | 0.02 |
| Current ratio | 2.50 | 3.09 | 3.37 | 3.71 | 2.82 | 3.13 | 2.62 | 3.48 | 4.98 | 6.89 |
| Quick ratio | 1.75 | 2.38 | 2.64 | 2.94 | 2.37 | 2.51 | 2.16 | 2.53 | 4.11 | 6.21 |
| Interest coverage | — | — | — | -285.6 | -588.7 | -287.4 | -461.9 | -341.2 | -354.7 | — |
| Working capital | $7.3M | $8.6M | $8.8M | $10.1M | $10.6M | $8.7M | $7.7M | $8.9M | $13.0M | $19.4M |
| Invested capital | $1.5M | −$658,000 | $3.6M | $5.0M | $2.7M | $3.8M | $2.8M | $7.3M | $5.8M | $4.4M |
| Tangible asset value | $3.1M | $4.4M | $6.1M | $8.0M | $8.7M | $5.4M | $5.6M | $10.5M | $15.3M | $21.4M |
| Net current asset value | $1.2M | $3.4M | $3.9M | $5.5M | $6.3M | $3.1M | $3.4M | $8.5M | $12.4M | $18.6M |
| Graham net-net per share | −$1.52 | $0.30 | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | $0 | $1,000 | $0 | — | — | $0 | $0 | $0 | $0 | $0 |
| Dividend payout ratio | — | — | — | — | — | — | — | — | — | 0.0% |
| Capex / revenue | 1.0% | 0.6% | 0.1% | 2.0% | 1.1% | 1.0% | 1.1% | 0.5% | 1.1% | 3.1% |
| Capex / depreciation | 1.38 | 0.58 | 0.10 | 2.15 | 0.74 | 0.79 | 0.66 | 0.22 | 0.38 | 1.59 |
| Stock-based compensation / revenue | 1.3% | 1.6% | 4.1% | 5.0% | 3.0% | 2.0% | 4.7% | 8.6% | 14.5% | 16.7% |
| R&D / revenue | 11.6% | 12.7% | 14.7% | 1.6% | 1.0% | 3.0% | 7.5% | 8.0% | 9.5% | 12.3% |
| SG&A / revenue | 38.9% | 51.5% | 59.5% | 66.6% | 77.2% | 50.7% | 76.2% | 99.0% | 120.7% | 134.2% |
| Efficiency | ||||||||||
| Days sales outstanding | 86.0 | 124.6 | 122.8 | 68.5 | 75.3 | 66.4 | 75.9 | 48.3 | 39.9 | 51.5 |
| Days of inventory on hand | 98.9 | 116.5 | 127.4 | 114.6 | 109.8 | 71.4 | 104.2 | 113.5 | 99.3 | 98.5 |
| Days payables outstanding | 43.3 | 32.3 | 33.1 | 51.5 | 72.1 | 58.0 | 61.8 | 45.7 | 49.3 | 66.1 |
| Cash conversion cycle (days) | 141.5 | 208.9 | 217.1 | 131.5 | 113.0 | 79.8 | 118.3 | 116.0 | 89.9 | 83.8 |
| Receivables turnover | 4.25 | 2.93 | 2.97 | 5.33 | 4.84 | 5.50 | 4.81 | 7.56 | 9.14 | 7.09 |
| Payables turnover | 8.42 | 11.31 | 11.04 | 7.09 | 5.06 | 6.29 | 5.90 | 7.99 | 7.40 | 5.52 |
| Inventory turnover | 3.69 | 3.13 | 2.87 | 3.19 | 3.33 | 5.11 | 3.50 | 3.22 | 3.68 | 3.71 |
| Asset turnover | 1.41 | 1.01 | 0.82 | 0.76 | 0.75 | 1.26 | 1.24 | 1.13 | 0.75 | 0.65 |
| Average receivables | $4.6M | $4.9M | $4.3M | $2.5M | $2.6M | $3.4M | $3.7M | $2.5M | $1.8M | $1.8M |
| Average payables | $1.4M | $780,000 | $724,000 | $1.2M | $1.7M | $1.9M | $1.7M | $1.3M | $1.3M | $1.3M |
| Average inventory | $3.3M | $2.8M | $2.8M | $2.8M | $2.6M | $2.4M | $2.8M | $3.1M | $2.5M | $1.9M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from SNOA's annual financial statements (latest annual report filed June 16, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SNOA valuation and financial ratios
Sonoma Pharmaceuticals earned a return on equity of −84.6% and a return on invested capital of −441.9% in fiscal 2026. It ended the year with $0.8 million of debt and $2.4 million in cash and short-term investments, a net cash position of $1.6 million.
See the SNOA income statement, the SNOA chart for price history, or the SNOA stock overview for the latest quote and news.
SNOA key metrics FAQ
What is Sonoma Pharmaceuticals's return on equity?
Sonoma Pharmaceuticals's return on equity (ROE) was −84.6% in fiscal 2026: net income of -$3.2 million on average shareholders' equity of $3.8 million.
What is Sonoma Pharmaceuticals's ROIC?
Sonoma Pharmaceuticals's return on invested capital was −441.9% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Sonoma Pharmaceuticals have?
Sonoma Pharmaceuticals had total debt of $0.8 million at the end of fiscal 2026, a debt-to-equity ratio of 0.27 and more cash than debt.
What is Sonoma Pharmaceuticals's free cash flow yield?
Sonoma Pharmaceuticals generated -$4.1 million of free cash flow in fiscal 2026, a free cash flow yield of −115.0% on its market value at year-end ($3.6 million).
What is Sonoma Pharmaceuticals's current ratio?
Sonoma Pharmaceuticals's current ratio was 2.50 at the end of fiscal 2026: current assets were 2.50 times current liabilities.